Telpegfilgrastim - Xiamen Amoytop Biotech
Alternative Names: Pegneugen; Telpegfilgrastim injection - Xiamen Amoytop Biotech; Y-shaped branched pegylated filgrastim - Xiamen Amoytop Biotech; YPEG-filgrastim - Xiamen Amoytop Biotech; YPEG-rhG-CSF - Xiamen Amoytop BiotechLatest Information Update: 21 Apr 2025
At a glance
- Originator Xiamen Amoytop Biotech
- Developer Sun Yat-Sen University; Xiamen Amoytop Biotech
- Class Antihypertensives; Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor replacements; Granulocyte colony-stimulating factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Chemotherapy induced febrile neutropenia
- Phase I Preeclampsia
Most Recent Events
- 15 Apr 2025 Xiamen Amoytop Biotech plans a phase-II trial for Chemotherapy induced febrile neutropenia (In adults, In adolescent, In children) in China (SC), (NCT06926751)
- 04 Apr 2025 Xiamen Amoytop Biotech plans a phase Ia pharmacokinetic and pharmacodynamic trial in Non-pregnant Females of Childbearing (In Volunteers) in China (SC) (NCT06924385)
- 26 Mar 2025 Phase-I clinical trials in Preeclampsia (In volunteers) in China (SC) (NCT06893796)